Who owns KARYOPHARM THERAPEUTICS INC COM NEW?
- Ticker: KPTI
- CUSIP Number: 48576u205
Tip: Access positions for across all investors
Analyze quarterly positions in Karyopharm Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Karyopharm Therapeutics stock
Who bought or sold KARYOPHARM THERAPEUTICS INC COM NEW this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management | 1.5M | $11M | 113% | Dec 2025 |
|
| Opaleye Management | 930k | $6.8M | 100% | Dec 2025 |
|
| Affinity Asset Advisors | 890k | $6.5M | 464% | Dec 2025 |
|
| Susquehanna International | 835k | $6.1M | 196% | Dec 2025 |
|
| Vanguard Group | 560k | $4.1M | 37% | Dec 2025 |
|
| Ikarian Capital | 545k | $4.0M | 1898% | Dec 2025 |
|
| Soleus Capital Management | 440k | $3.2M | 100% | Dec 2025 |
|
| Adage Capital Partners GP | 421k | $2.8M | 0% | Sep 2025 |
|
| Davidson Kempner Capital Management | 310k | $2.3M | 100% | Dec 2025 |
|
| Braidwell | 303k | $2.2M | 100% | Dec 2025 |
|
| Exome Asset Management | 296k | $2.2M | 100% | Dec 2025 |
|
| Ameriprise Financial | 277k | $2.0M | 100% | Dec 2025 |
|
| Boxer Capital Management | 253k | $1.9M | 100% | Dec 2025 |
|
| BlackRock | 248k | $1.8M | 7% | Dec 2025 |
|
| Geode Capital Management | 188k | $1.4M | 101% | Dec 2025 |
|
| Boothbay Fund Management | 145k | $1.1M | 100% | Dec 2025 |
|
| Catalio Capital Management | 143k | $1.1M | 0% | Dec 2025 |
|
| Avidity Partners Management | 135k | $990k | 0% | Dec 2025 |
|
| Marshall Wace | 129k | $945k | 0% | Dec 2025 |
|
| Group One Trading | 102k | $754k | 50% | Dec 2025 |
|
| CAM Group Holding A/S | 100k | $736k | 0% | Dec 2025 |
|
| Walleye Trading Advisors | 96k | $704k | 100% | Dec 2025 |
|
| Citadel Advisors | 92k | $602k | -59% | Sep 2025 |
|
| Jane Street | 91k | $672k | 608% | Dec 2025 |
|
| UBS Group | 89k | $651k | 48% | Dec 2025 |
|
| Context Capital Management | 63k | $464k | 100% | Dec 2025 |
|
| Renaissance Technologies | 60k | $441k | -7% | Dec 2025 |
|
| Quadrature Capital | 60k | $440k | 100% | Dec 2025 |
|
| State Street Corporation | 59k | $434k | 27% | Dec 2025 |
|
| Connor, Clark & Lunn Investment Management | 57k | $421k | 100% | Dec 2025 |
|
| Jump Financial | 54k | $397k | 100% | Dec 2025 |
|
| DAFNA Capital Management | 51k | $375k | 100% | Dec 2025 |
|
| ADAR1 Capital Management | 50k | $368k | 100% | Dec 2025 |
|
| Trexquant Investment | 42k | $307k | 100% | Dec 2025 |
|
| Silverback Asset Management | 40k | $262k | -43% | Sep 2025 |
|
| Bridgeway Capital Management | 35k | $228k | -8% | Sep 2025 |
|
| Simplex Trading | 33k | $242k | 461% | Dec 2025 |
|
| Northern Trust | 29k | $214k | 54% | Dec 2025 |
|
| Baird Financial | 28k | $206k | 8% | Dec 2025 |
|
| Persistent Asset Partners | 18k | $135k | 100% | Dec 2025 |
|
| Belvedere Trading | 12k | $91k | -18% | Dec 2025 |
|
| XTX Topco | 12k | $88k | -17% | Dec 2025 |
|
| Bank of New York Mellon | 11k | $82k | 0% | Dec 2025 |
|
| CI Private Wealth | 10k | $10k | 100% | Dec 2025 |
|
| Royal Bank of Canada | 6.7k | $44k | -9% | Sep 2025 |
|
| Barclays | 4.1k | $30k | 0% | Dec 2025 |
|
| Acadian Asset Management | 3.7k | $27k | 100% | Dec 2025 |
|
| TD Waterhouse Canada | 3.2k | $24k | 0% | Dec 2025 |
|
| Rockefeller Capital Management | 733.00 | $5.4k | 100% | Dec 2025 |
|
| FMR | 679.00 | $4.4k | -11% | Sep 2025 |
|
| Jpmorgan Chase & Co | 550.00 | $3.6k | 100% | Sep 2025 |
|
| Aspect Partners | 391.00 | $2.9k | 100% | Dec 2025 |
|
| Advisor Group Holdings | 282.00 | $2.1k | -18% | Dec 2025 |
|
| Quent Capital | 235.00 | $1.7k | 2% | Dec 2025 |
|
| Mb, Levis & Associates | 100.00 | $736.000000 | 0% | Dec 2025 |
|
| Harbour Investments | 85.00 | $625.999500 | 0% | Dec 2025 |
|
| Bnp Paribas Arbitrage, Snc | 82.00 | $604.003800 | 0% | Dec 2025 |
|
| SBI Securities | 74.00 | $545.002600 | 0% | Dec 2025 |
|
| Activest Wealth Management | 66.00 | $485.997600 | 0% | Dec 2025 |
|
| Hanson McClain Advisors | 26.00 | $191.999600 | 0% | Dec 2025 |
|
| West Branch Capital | 3.00 | $23.000100 | 0% | Dec 2025 |
|
| Atlantic Trust | 3.00 | $21.999900 | 0% | Dec 2025 |
|
Who sold out of Karyopharm Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Palo Alto Investors | Jun 2025 | 188k | $810k |
| Millennium Management | Jun 2025 | 32k | $137k |
| Goldman Sachs Group | Sep 2025 | 25k | $163k |
| GSA Capital Partners | Sep 2025 | 14k | $92k |
| Tower Research Capital | Sep 2025 | 1.1k | $7.1k |
| Rise Advisors | Sep 2025 | 131.00 | $857.002000 |
| Fortitude Family Office | Sep 2025 | 81.00 | $529.999200 |
| Bruce G. Allen Investments | Sep 2025 | 22.00 | $144.001000 |
| Advisory Services Network | Sep 2025 | 12.00 | $78.000000 |
| Pittenger & Anderson | Sep 2025 | 3.00 | $20.000100 |